$GILD Company News Apple, Facebook pressured a
Post# of 145120
Posted On: 04/23/2014 10:47:22 AM
$GILD Company News
Apple, Facebook pressured ahead of earnings 18 min ago - Saumya Vaishampayan
U.S. stocks fall; PMI, home sales disappoint 22 min ago - Anora Mahmudova
U.S. stock futures pause after six-session win streak 8:57 a.m. Today - Sara Sjolin
Game day for Facebook and Apple, volume 'signalling the nasty' 6:50 a.m. Today - blogs.marketwatch.com
Apple, Facebook, Boeing are stocks to watch 5:30 a.m. Today - Sue Chang
Gilead shares climb; AT&T, Amgen shares fall 5:55 p.m. April 22, 2014 - Myra P. Saefong
Gilead scores big on earnings with new drug, but investors getting wary 5:46 p.m. April 22, 2014 - blogs.marketwatch.com
Gilead earnings buoyed by Hepatitis-C drug 5:04 p.m. April 22, 2014 - Anna Prior
Gilead Sciences shares up 4.5% in after-hours trade 4:35 p.m. April 22, 2014 - Myra P. Saefong
Gilead beats expectations; Sovaldi sales hit $2.3 bln 4:22 p.m. April 22, 2014 - Claudia Assis
Gilead: Hep C drug Sovaldi sells $2.27 billion 4:17 p.m. April 22, 2014 - Claudia Assis
Gilead Sciences Q1 non GAAP EPS $1.48 vs. 48c 4:15 p.m. April 22, 2014 - Claudia Assis
Should doctors care what treatments cost? 4:14 p.m. April 22, 2014 - blogs.marketwatch.com
Gilead shares to resume trade at 4:30 Eastern 4:09 p.m. April 22, 2014 - Laura Mandaro
Gilead shares are halted 4:03 p.m. April 22, 2014 - Laura Mandaro
S&P 500, Nasdaq extend win streak to 6 sessions: Stock market live blog recap 3:56 p.m. April 22, 2014 - blogs.marketwatch.com
Scouring the moonscape for leading stocks 3:01 p.m. April 22, 2014 - The Trading Deck
Centene shrugs off drug costs, Obamacare and beats profit views 2:42 p.m. April 22, 2014 - blogs.marketwatch.com
I have no qualms about taking Gilead’s $84,000 drug 7:30 a.m. April 22, 2014 - Tim Mullaney
Apple, Microsoft are not the keys to this week’s news 7:00 a.m. April 22, 2014 - Marek Fuchs
Market Hustle: Stocks Weak After Tepid China, Drop in U.S. Home Sales 22 min ago - TheStreet.com
Stock Market News for April 23, 2014 - Market News 41 min ago - Zacks.com
Gilead (GILD) On Momo Momentum Watch Today 58 min ago - TheStreet.com
Big Biotech Is On The Move 9:47 a.m. Today - Seeking Alpha
Amgen's Q1 Earnings Decline Y/Y - Analyst Blog 9:40 a.m. Today - Zacks.com
5 Stocks to Lose Post-Earnings - Analyst Blog 9:12 a.m. Today - Zacks.com
Gilead: X-Marks The Spot For Sovaldi Sales 9:05 a.m. Today - Seeking Alpha
Why Gilead Sciences (GILD) Stock Is Higher This Morning 9:01 a.m. Today - TheStreet.com
Sovaldi's Q1 Is A Home Run With Men On Base; Why Gilead May Triple From Here 8:52 a.m. Today - Seeking Alpha
Do The Math: Ram Selvaraju On The Appeal Of Biotechs In Orphan Diseases 8:48 a.m. Today - Seeking Alpha
Morning Market Movers 8:44 a.m. Today - benzinga.com
Market Hustle: Stock Futures Turn Lower on Weak China Data; P&G Revenue Slips 8:35 a.m. Today - TheStreet.com
How Did Analysts Get Gilead's Earnings Completely Wrong? 8:19 a.m. Today - benzinga.com
5 Biotech Stocks Ready To Resume their Rally 8:16 a.m. Today - Barrons.com
UBS Top Stocks to Buy Working for Cancer Cures 7:52 a.m. Today - 247WallSt.com
Stock Futures Dip as Traders Eye Corporate Earnings 7:21 a.m. Today - FOXBusiness
Stocks Slip as Traders Review Earnings, Data 7:21 a.m. Today - FOXBusiness
Benzinga's Top #PreMarket Gainers 7:09 a.m. Today - benzinga.com
ETF Outlook For Wednesday, April 23, 2014 (MGC, IYZ, TAN, BBH, GILD, T) 6:41 a.m. Today - Benzinga.com
Wall Street Breakfast: Must-Know News 6:31 a.m. Today - Seeking Alpha
Gilead Sciences Announces First Quarter 2014 Financial Results 4:03 p.m. April 22, 2014 - BusinessWire - BZX
Gilead Sciences’ New Drug Applications for Cobicistat and Elvitegravir for HIV Therapy Accepted by U.S. FDA 4:30 p.m. April 21, 2014 - BusinessWire - BZX
Young Scientists From Around the State Will Compete for Top Honors at the 63rd California State Science Fair 6:31 p.m. April 16, 2014 - PR Newswire - PRF
Gilead Sciences to Release First Quarter 2014 Financial Results on Tuesday, April 22, 2014 5:00 p.m. April 15, 2014 - BusinessWire - BZX
AHF: Anti-Gilead Drug Pricing Campaign Picks Up Steam 2:24 p.m. April 14, 2014 - BusinessWire - BZX
Financial Release Dates -- Research on Gilead Sciences, Juniper Networks, FirstCommonwealth Financial, and Genuine Parts 9:00 a.m. April 14, 2014 - PR Newswire - PRF
Final Data from the Phase 2 COSMOS Study of Janssen’s Once-Daily Simeprevir in Combination with Sofosbuvir Presented at the International Liver Congress™ 2014 of the European Association for the Study of the Liver (EASL) 11:24 a.m. April 12, 2014 - BusinessWire - BZX
Final Data from the Phase 2 COSMOS Study of Janssen's Once-Daily Simeprevir in Combination with Sofosbuvir Presented at The International Liver Congress™ 2014 of the European Association for the Study of the Liver (EASL) 11:15 a.m. April 12, 2014 - PR Newswire - PRF
Final Data from the Phase 2 COSMOS Study of Janssen's Once-Daily Simeprevir in Combination with Sofosbuvir Presented at The International Liver Congress™ 2014 of the European Association for the Study of the Liver (EASL) 11:15 a.m. April 12, 2014 - PR Newswire - PRF
Priority Reviews, Preliminary Earnings Releases, Clinical Trials Results, and Launch of Website - Analyst Notes on Gilead, Pfizer, Intuitive Surgical, Alkermes and Quest 10:14 a.m. April 11, 2014 - PR Newswire - PRF
Today's Review on Active Stocks -- Research on Ashford Hospitality Trust, Dejour Energy, North American Palladium, and Gilead Sciences 1:30 p.m. April 10, 2014 - PR Newswire - PRF
Emerging Therapies in Development for Relapsed/Refractory CLL/SLL are Expected to Offer Efficacy Benefits Over Currently Available Treatments 10:00 a.m. April 10, 2014 - PR Newswire - PRF
Gilead Announces Phase 2 Results for Two Investigational All-Oral Sofosbuvir-Based Regimens for the Treatment of Chronic Hepatitis C 1:02 a.m. April 10, 2014 - BusinessWire - BZX
Clinical Trial Results Presentation and Publication, and Upcoming Exhibit - Analyst Notes on Gilead Sciences, Agios, Mindray, BG Medicine, and Ultragenyx 8:00 a.m. April 9, 2014 - PR Newswire - PRF
Gilead Announces U.S. FDA Priority Review Designation for Ledipasvir/Sofosbuvir Fixed-Dose Combination Tablet for Chronic Hepatitis C Genotype 1 Infection 8:31 a.m. April 7, 2014 - BusinessWire - BZX
Senior Notes Conversions, FDA Drug Approvals, Acquisitions, Stock Price Updates, and Clinical Trial Studies - Analyst Notes on Gilead, Pfizer, Nordion, Intuitive Surgical, and Novartis 8:00 a.m. April 3, 2014 - PR Newswire - PRF
Gilead Announces Results From Phase 3 Study of Sofosbuvir Among Hepatitis C Patients in Japan 4:30 p.m. April 2, 2014 - BusinessWire - BZX
Critical Alerts For Ford, Castlight Health, Gilead Sciences, Take Two Interactive, and Qihoo 360 Released By InvestorsObserver 9:31 a.m. April 2, 2014 - PR Newswire - PRF
Pending Applications, Closed Public Offering, Joint Venture Formation, Executive Appointment, and Commercial Launch - Analyst Notes on Gilead, Enzymotec, Intrexon, Advaxis, and Repligen 8:00 a.m. April 1, 2014 - PR Newswire - PRF
Comprehensive Technical Coverage on Active Equities -- Research on Sirius XM, Gilead Sciences, Microsoft, and Yahoo! 12:03 p.m. March 31, 2014 - PR Newswire - PRF
Apple, Facebook pressured ahead of earnings 18 min ago - Saumya Vaishampayan
U.S. stocks fall; PMI, home sales disappoint 22 min ago - Anora Mahmudova
U.S. stock futures pause after six-session win streak 8:57 a.m. Today - Sara Sjolin
Game day for Facebook and Apple, volume 'signalling the nasty' 6:50 a.m. Today - blogs.marketwatch.com
Apple, Facebook, Boeing are stocks to watch 5:30 a.m. Today - Sue Chang
Gilead shares climb; AT&T, Amgen shares fall 5:55 p.m. April 22, 2014 - Myra P. Saefong
Gilead scores big on earnings with new drug, but investors getting wary 5:46 p.m. April 22, 2014 - blogs.marketwatch.com
Gilead earnings buoyed by Hepatitis-C drug 5:04 p.m. April 22, 2014 - Anna Prior
Gilead Sciences shares up 4.5% in after-hours trade 4:35 p.m. April 22, 2014 - Myra P. Saefong
Gilead beats expectations; Sovaldi sales hit $2.3 bln 4:22 p.m. April 22, 2014 - Claudia Assis
Gilead: Hep C drug Sovaldi sells $2.27 billion 4:17 p.m. April 22, 2014 - Claudia Assis
Gilead Sciences Q1 non GAAP EPS $1.48 vs. 48c 4:15 p.m. April 22, 2014 - Claudia Assis
Should doctors care what treatments cost? 4:14 p.m. April 22, 2014 - blogs.marketwatch.com
Gilead shares to resume trade at 4:30 Eastern 4:09 p.m. April 22, 2014 - Laura Mandaro
Gilead shares are halted 4:03 p.m. April 22, 2014 - Laura Mandaro
S&P 500, Nasdaq extend win streak to 6 sessions: Stock market live blog recap 3:56 p.m. April 22, 2014 - blogs.marketwatch.com
Scouring the moonscape for leading stocks 3:01 p.m. April 22, 2014 - The Trading Deck
Centene shrugs off drug costs, Obamacare and beats profit views 2:42 p.m. April 22, 2014 - blogs.marketwatch.com
I have no qualms about taking Gilead’s $84,000 drug 7:30 a.m. April 22, 2014 - Tim Mullaney
Apple, Microsoft are not the keys to this week’s news 7:00 a.m. April 22, 2014 - Marek Fuchs
Market Hustle: Stocks Weak After Tepid China, Drop in U.S. Home Sales 22 min ago - TheStreet.com
Stock Market News for April 23, 2014 - Market News 41 min ago - Zacks.com
Gilead (GILD) On Momo Momentum Watch Today 58 min ago - TheStreet.com
Big Biotech Is On The Move 9:47 a.m. Today - Seeking Alpha
Amgen's Q1 Earnings Decline Y/Y - Analyst Blog 9:40 a.m. Today - Zacks.com
5 Stocks to Lose Post-Earnings - Analyst Blog 9:12 a.m. Today - Zacks.com
Gilead: X-Marks The Spot For Sovaldi Sales 9:05 a.m. Today - Seeking Alpha
Why Gilead Sciences (GILD) Stock Is Higher This Morning 9:01 a.m. Today - TheStreet.com
Sovaldi's Q1 Is A Home Run With Men On Base; Why Gilead May Triple From Here 8:52 a.m. Today - Seeking Alpha
Do The Math: Ram Selvaraju On The Appeal Of Biotechs In Orphan Diseases 8:48 a.m. Today - Seeking Alpha
Morning Market Movers 8:44 a.m. Today - benzinga.com
Market Hustle: Stock Futures Turn Lower on Weak China Data; P&G Revenue Slips 8:35 a.m. Today - TheStreet.com
How Did Analysts Get Gilead's Earnings Completely Wrong? 8:19 a.m. Today - benzinga.com
5 Biotech Stocks Ready To Resume their Rally 8:16 a.m. Today - Barrons.com
UBS Top Stocks to Buy Working for Cancer Cures 7:52 a.m. Today - 247WallSt.com
Stock Futures Dip as Traders Eye Corporate Earnings 7:21 a.m. Today - FOXBusiness
Stocks Slip as Traders Review Earnings, Data 7:21 a.m. Today - FOXBusiness
Benzinga's Top #PreMarket Gainers 7:09 a.m. Today - benzinga.com
ETF Outlook For Wednesday, April 23, 2014 (MGC, IYZ, TAN, BBH, GILD, T) 6:41 a.m. Today - Benzinga.com
Wall Street Breakfast: Must-Know News 6:31 a.m. Today - Seeking Alpha
Gilead Sciences Announces First Quarter 2014 Financial Results 4:03 p.m. April 22, 2014 - BusinessWire - BZX
Gilead Sciences’ New Drug Applications for Cobicistat and Elvitegravir for HIV Therapy Accepted by U.S. FDA 4:30 p.m. April 21, 2014 - BusinessWire - BZX
Young Scientists From Around the State Will Compete for Top Honors at the 63rd California State Science Fair 6:31 p.m. April 16, 2014 - PR Newswire - PRF
Gilead Sciences to Release First Quarter 2014 Financial Results on Tuesday, April 22, 2014 5:00 p.m. April 15, 2014 - BusinessWire - BZX
AHF: Anti-Gilead Drug Pricing Campaign Picks Up Steam 2:24 p.m. April 14, 2014 - BusinessWire - BZX
Financial Release Dates -- Research on Gilead Sciences, Juniper Networks, FirstCommonwealth Financial, and Genuine Parts 9:00 a.m. April 14, 2014 - PR Newswire - PRF
Final Data from the Phase 2 COSMOS Study of Janssen’s Once-Daily Simeprevir in Combination with Sofosbuvir Presented at the International Liver Congress™ 2014 of the European Association for the Study of the Liver (EASL) 11:24 a.m. April 12, 2014 - BusinessWire - BZX
Final Data from the Phase 2 COSMOS Study of Janssen's Once-Daily Simeprevir in Combination with Sofosbuvir Presented at The International Liver Congress™ 2014 of the European Association for the Study of the Liver (EASL) 11:15 a.m. April 12, 2014 - PR Newswire - PRF
Final Data from the Phase 2 COSMOS Study of Janssen's Once-Daily Simeprevir in Combination with Sofosbuvir Presented at The International Liver Congress™ 2014 of the European Association for the Study of the Liver (EASL) 11:15 a.m. April 12, 2014 - PR Newswire - PRF
Priority Reviews, Preliminary Earnings Releases, Clinical Trials Results, and Launch of Website - Analyst Notes on Gilead, Pfizer, Intuitive Surgical, Alkermes and Quest 10:14 a.m. April 11, 2014 - PR Newswire - PRF
Today's Review on Active Stocks -- Research on Ashford Hospitality Trust, Dejour Energy, North American Palladium, and Gilead Sciences 1:30 p.m. April 10, 2014 - PR Newswire - PRF
Emerging Therapies in Development for Relapsed/Refractory CLL/SLL are Expected to Offer Efficacy Benefits Over Currently Available Treatments 10:00 a.m. April 10, 2014 - PR Newswire - PRF
Gilead Announces Phase 2 Results for Two Investigational All-Oral Sofosbuvir-Based Regimens for the Treatment of Chronic Hepatitis C 1:02 a.m. April 10, 2014 - BusinessWire - BZX
Clinical Trial Results Presentation and Publication, and Upcoming Exhibit - Analyst Notes on Gilead Sciences, Agios, Mindray, BG Medicine, and Ultragenyx 8:00 a.m. April 9, 2014 - PR Newswire - PRF
Gilead Announces U.S. FDA Priority Review Designation for Ledipasvir/Sofosbuvir Fixed-Dose Combination Tablet for Chronic Hepatitis C Genotype 1 Infection 8:31 a.m. April 7, 2014 - BusinessWire - BZX
Senior Notes Conversions, FDA Drug Approvals, Acquisitions, Stock Price Updates, and Clinical Trial Studies - Analyst Notes on Gilead, Pfizer, Nordion, Intuitive Surgical, and Novartis 8:00 a.m. April 3, 2014 - PR Newswire - PRF
Gilead Announces Results From Phase 3 Study of Sofosbuvir Among Hepatitis C Patients in Japan 4:30 p.m. April 2, 2014 - BusinessWire - BZX
Critical Alerts For Ford, Castlight Health, Gilead Sciences, Take Two Interactive, and Qihoo 360 Released By InvestorsObserver 9:31 a.m. April 2, 2014 - PR Newswire - PRF
Pending Applications, Closed Public Offering, Joint Venture Formation, Executive Appointment, and Commercial Launch - Analyst Notes on Gilead, Enzymotec, Intrexon, Advaxis, and Repligen 8:00 a.m. April 1, 2014 - PR Newswire - PRF
Comprehensive Technical Coverage on Active Equities -- Research on Sirius XM, Gilead Sciences, Microsoft, and Yahoo! 12:03 p.m. March 31, 2014 - PR Newswire - PRF
(0)
(0)